溴尿嘧啶
化学
多发性骨髓瘤
脚手架
癌症研究
药理学
计算生物学
组合化学
生物化学
内科学
表观遗传学
程序设计语言
计算机科学
医学
生物
基因
作者
Zonglong Chen,Hong Yang,Yan Zhang,Xiaodong Lyu,Qiongyu Shi,Cheng Zhang,Xingcan Wang,Zekun Wang,Ying Zhang,Yue Wen Deng,Yujie Wang,Yuting Huang,Yong Xu,Xun Huang,Yingxia Li
标识
DOI:10.1021/acs.jmedchem.4c01984
摘要
E1A binding protein (p300) is a promising therapeutic target for the treatment of cancer. Herein, we report the discovery of a series of novel inhibitors with an ( S )-3-fluoropyrrolidin-2-one scaffold targeting p300 bromodomain. The best compound 29 (CZL-046) shows potent inhibitory activity of p300 bromodomain (IC 50 = 3.3 nM) and antiproliferative activity in the multiple myeloma (MM) cell line (OPM-2 IC 50 = 51.5 nM). 29 suppressed the mRNA levels of c-Myc and IRF4 and downregulated the expression of c-Myc and H3K27Ac. Compared to the lead compound 5, 29 exhibits significantly improved in vitro and in vivo metabolic properties. Oral administration of 29 with 30 mg/kg achieved a TGI value of 44% in the OPM-2 xenograft model, accompanied by good tolerability. The cocrystal structure of CREB binding protein bromodomain with 29 provides an insight into the precise binding mode. The results demonstrate that 29 is a promising p300 bromodomain inhibitor for the treatment of MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI